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Abstract 
Background: Alcohol withdrawal syndrome (AWS) is routinely treated with B‑vitamins. However, the relationship 
between thiamine status and outcome is rarely examined. The aim of the present study was to examine the relation‑
ship between thiamine and magnesium status in patients with AWS.
Methods: Patients (n = 127) presenting to the Emergency Department with AWS were recruited to a prospective 
observational study. Blood samples were drawn to measure whole blood thiamine diphosphate (TDP) and serum 
magnesium concentrations. Routine biochemistry and haematology assays were also conducted. The Glasgow Modi‑
fied Alcohol Withdrawal Score (GMAWS) measured severity of AWS. Seizure history and current medications were also 
recorded.
Results: The majority of patients (99%) had whole blood TDP concentration within/above the reference interval 
(275–675 ng/gHb) and had been prescribed thiamine (70%). In contrast, the majority of patients (60%) had low serum 
magnesium concentrations (< 0.75 mmol/L) and had not been prescribed magnesium (93%). The majority of patients 
(66%) had plasma lactate concentrations above 2.0 mmol/L. At 1 year, 13 patients with AWS had died giving a mortal‑
ity rate of 11%. Male gender (p < 0.05), BMI < 20 kg/m2 (p < 0.01), GMAWS max ≥ 4 (p < 0.05), elevated plasma lactate 
(p < 0.01), low albumin (p < 0.05) and elevated serum CRP (p < 0.05) were associated with greater 1‑year mortality. Also, 
low serum magnesium at time of recruitment to study and low serum magnesium at next admission were associated 
with higher 1‑year mortality rates, (84% and 100% respectively; both p < 0.05).
Conclusion: The prevalence of low circulating thiamine concentrations were rare and it was regularly prescribed in 
patients with AWS. In contrast, low serum magnesium concentrations were common and not prescribed. Low serum 
magnesium was associated more severe AWS and increased 1‑year mortality.
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Background
Despite public health measures, alcohol consumption has 
continued to rise in the USA and UK over the past three 
decades [1–3]. In the USA, the number of alcohol related 
deaths is reported to have increased by 35% between 
2007 and 2017 [4], while Scotland is reported to have the 
highest alcohol related death rate in the UK [5]. Despite 
these recent epidemiological reports, there is a paucity 
of data available in the literature related to mortality for 
patients following an episode of alcohol withdrawal syn-
drome (AWS) [6].
Alcohol exerts direct and indirect effects on cellular 
energy metabolism and alcohol use disorder (AUD) is a 
complex psychological and pathophysiological problem 
[7, 8]. Nutritional and social factors may be protective 
or contributory, however a threshold may be reached 
beyond which alcohol related compromise of oxidative 
resilience manifests in accelerated organ/system specific 
final common pathways of biochemical and clinical dete-
rioration [7, 9]. The occurrence of alcohol withdrawal 
syndrome (AWS) may represent the crossing of that 
threshold [9].
Standard treatment of AWS is predicated upon early 
provision of benzodiazepine treatment to ameliorate 
symptoms and prevent progression to AWS seizures, 
mainly by restoring the balance between the N-methyl-
d-aspartate (NMDA) and gamma-aminobutyric acid 
(GABA) receptor activity at the synapse [10, 11]. Ben-
zodiazepines replicate the GABA enhancing effect of 
alcohol on the CNS, thus down-regulating excitatory 
NMDA activity and preventing progression of alcohol 
withdrawal syndrome and seizures [10, 11]. In addition, 
there is empirical provision of thiamine in the form of 
B-vitamins over the period of hospitalization. For exam-
ple, B-vitamins are administered to mitigate against the 
risk of thiamine deficiency related neurodegenerative 
conditions (e.g. Wernicke-Korsakoff syndrome) that are 
known to occur in alcohol use disorder patients due to 
compromise of key enzymes involved in intermediary 
metabolism [12, 13]. Thiamine in the form of thiamine 
diphosphate (TDP) is required as a co-factor for pyruvate 
dehydrogenase (PDH) and alpha ketoglutaric acid dehy-
drogenase (KGDH), both key enzymes in Krebs cycle 
(Fig.  1). Thiamine also requires magnesium for absorp-
tion from the GI tract [14], activation to its active form 
(TDP) [15] and for optimal activity of thiamine depend-
ent enzymes within the cell [16, 17]. Thiamine and/or 
magnesium deficiency may compromise these enzymes 
and result in altered metabolism of glucose and increased 
lactate production (Fig. 2) [18, 19]. Therefore, in the con-
text of normal partial pressure tissue oxygen concentra-
tions and in the absence of an inflammatory response or 
intense skeletal muscle activity (e.g. alcohol withdrawal 
seizure), thiamine and/or magnesium deficiency medi-
ated increase in metabolism of glucose to lactate may 
represent pseudo-hypoxic disruption of normal glucose 
metabolism [7, 20].
Despite the prevalence of alcohol dependence in the 
western world, accurate data for thiamine deficiency 
is not available, with thiamine deficiency recorded as 
being between 30–80% in the AUD population [21, 22]. 
Furthermore, there is a paucity of accurate evidence to 
guide clinicians regarding the dose and duration of thia-
mine treatment or prophylaxis for Wernicke’s encepha-
lopathy (WE) [22, 23]. It has been observed that WE 
can occur in the context of apparently normal blood 
thiamine levels [24]. Case reports have accrued over the 
past four decades, which point to a role for magnesium 
in patients who remain refractory to thiamine treatment, 
and respond to concurrent administration of intravenous 
magnesium [25–27]. Despite these case reports and the 
biochemical evidence in favor of an enhanced response 
to thiamine therapy when administered with magnesium 
[16, 17, 28, 29], the potential relationship between thia-
mine and magnesium has remained largely unexplored in 
a clinical context.
We recently reported in a retrospective study that 
patients who experienced an episode of alcohol with-
drawal syndrome received thiamine supplementation 
although thiamine diphosphate (TDP) concentrations 
were not determined. In contrast, serum magnesium 
concentrations were measured and patients who had low 
serum magnesium concentrations  (Mg2+ < 0.75 mmol/L) 
were rarely supplemented and were four times more 
likely to die at 1 year [9]. Furthermore, there was little 
supplementation of such low magnesium concentrations 
following discharge from hospital. Therefore, treatment 
of AUD, based on combined thiamine and magnesium 
supplementation is not well standardized in either the 
acute or chronic setting.
To validate the above findings, a prospective study 
was carried out of the relationship between circulating 
concentrations of thiamine and magnesium, the sub-
strates and products of intermediary metabolism, the 
Keywords: Alcohol withdrawal syndrome (AWS), Serum magnesium concentration, Circulating thiamine 
diphosphate (TDP), Pseudo‑hypoxia, Plasma lactate concentrations, Glasgow modified alcohol withdrawal scale 
(GMAWS), Seizure kindling, 1‑year mortality
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Fig. 1 ‘Clean burn’ metabolism with normal lactate and glutamate production
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Fig. 2 ‘Dirty burn’ metabolism: Pseudo‑hypoxic dysregulation of glucose metabolism with increased production of lactate and excitatory glutamate 
in patients with AWS
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clinicopathological characteristics of AWS and 1-year 
mortality in patients with AWS.
Patients and methods
The study took place in the Emergency Department of 
Glasgow Royal Infirmary (GRI) between December 2016 
and February 2018. GRI is a university teaching hospi-
tal that serves an urban population with a high burden 
of socio-economic deprivation and offers the full spec-
trum of adult acute receiving specialties to patients over 
16 years old [30, 31]. The study was approved by the West 
of Scotland Research Ethics Committee (WoS REC: 16/
WS/0162).
Age, sex, BMI and documented evidence of AWS 
were considered minimal criteria for inclusion (n = 127). 
Patients displaying clinical signs or reporting symptoms 
consistent with AWS at presentation to triage in the 
Emergency Department were approached in triage, or 
as soon as possible thereafter, regarding consent for par-
ticipation in the study. As per routine clinical practice in 
the Emergency Department at GRI, patients were scored 
on the Glasgow Modified Alcohol Withdrawal Scale 
(GMAWS) and provided with standard benzodiazepine 
treatment for AWS (Fig. 3).
GMAWS is a validated score of severity of alcohol with-
drawal syndrome that allocates a score (0–2) to five clini-
cal characteristics (tremor, anxiety, sweating, orientation, 
hallucinations) (Fig. 3) [6]. GMAWS determines the dose 
of benzodiazepine treatment that is titrated and the time 
interval to re-administering the GMAWS scoring tool 
according to the score achieved (i.e. the severity of alco-
hol withdrawal). Diazepam (P.O.) or lorazepam (P.O. or 
I.V.) is administered as per GMAWS protocol. For the 
purposes of this study a ‘diazepam equivalent dose’ of 
benzodiazepine treatment was recorded, where diazepam 
10 mg was equivalent to lorazepam 1 mg. A GMAWS ≥ 4 
is considered severe, and is approximately equivalent 
to a Clinical Institute Withdrawal Assessment-Alcohol 
Revised (CIWA-Ar) scale ≥ 16 [6].
Bloods were drawn for routine biochemistry/haema-
tology and study samples prior to administration of par-
enteral thiamine  (Pabrinex®).  Pabrinex® is a two-vial 
multi-vitamin preparation that is administered intrave-
nously in 100  ml normal saline over 30  min.  Pabrinex® 
contains thiamine hydrochloride 250  mg, nicotinamide 
160 mg, pyridoxine hydrochloride 50 mg, riboflavin 4 mg 
and ascorbic acid 500  mg/10  mL [32]. A standard dose 
is 2 pairs of vials 1 and 2, administered TDS for 2 days 
[32–34].
Whole blood EDTA samples for thiamine diphos-
phate measurement were frozen at -70  °C and analyzed 
within 10 days of being drawn. Measurement of thia-
mine diphosphate in whole blood involved HPLC iso-
cratic separation with post-column derivatization using 
Fig. 3 Glasgow Modified Alcohol Withdrawal Scale (GMAWS)
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sodium hydroxide and potassium ferricyanide and fluo-
rescent detection. Results were expressed as nanogram of 
thiamine diphosphate per gram of haemoglobin (ng/gHb) 
[35].
A questionnaire was administered regarding recent 
weight loss, recent difficulty walking, smoking history, 
previous AWS episodes, previous AWS related seizures 
and use of ‘over the counter’ vitamin or magnesium sup-
plements. Data relating to daily alcohol consumption 
were also recorded. Electronic patient records were also 
examined for data relating to past medical history and 
current medications.
Following completion of the study, electronic patient 
records were re-examined to record serum magnesium 
concentrations in patients during their next unplanned 
admission. Electronic patient records were also re-exam-
ined to record 1-year mortality in patients who had been 
entered into the study.
Standard thresholds were applied to the data. Continu-
ous data were analyzed using the Mann–Whitney U test 
and categorical data were analyzed using the Chi squared 
test. Continuous data are presented as a median value and 
related inter-quartile range (IQR). Binary logistic regres-
sion analysis data was undertaken to examine the rela-
tionship between the severity of AWS (GMAWS </≥ 4) 
and independent variables. Data were analyzed in SPSS 
(Version 25.0. SPSS Inc., Chicago, IL, USA).
Results
Only 3 patients who were screened for inclusion in the 
study at triage were found to have on-going active evi-
dence of delirium. These patients were not recruited to 
the study, as they lacked capacity to consent. All patients 
(n = 127) recruited to the study fulfilled the criteria for 
inclusion with age, sex, BMI and documented evidence 
of alcohol withdrawal syndrome. Patients with 2 obser-
vations (n = 12) were excluded, leaving 115 patients for 
analysis.
The majority of patients (85%) reported previous epi-
sodes of alcohol withdrawal syndrome and had a docu-
mented history of previous alcohol withdrawal seizure 
(60%). Of the patients recruited to the study, 28% had suf-
fered a tonic–clonic seizure within the 12-h period prior 
to presentation to the Emergency Department and 97% 
of these patients had a documented history of previous 
alcohol withdrawal seizures. Patients who had a previ-
ous history of AWS had higher GMAWS scores (p < 0.05), 
higher benzodiazepine requirement (p < 0.001) and more 
frequent previous admissions (p < 0.01) than those who 
had not previously experienced AWS.
Twenty-five patients (22%) recruited to the study pro-
gressed to develop delirium tremens and three patients 
(3%) suffered a tonic–clonic seizure during the course of 
the study related admission.
The clinicopathological characteristics are shown in 
Table  1. The majority of patients were < 50  years old 
(65%), male (76%), not underweight (80%), had a severe 
alcohol withdrawal score (GMAWS max score ≥ 4) (65%) 
and the total ‘diazepam-equivalent’ dose of benzodiaz-
epine (BDZ) administered was more than 120 mg (51%). 
Of the laboratory analysis, the majority of patients had 
bilirubin (57%), alkaline phosphatase (67%), albumin 
(76%), CRP (56%), AST/ALT ratio (64%), glucose (66%), 
urea (67%), sodium (69%), potassium (81%), MCV (52%) 
and platelets (68%) within the laboratory reference inter-
val. The majority of patients had been prescribed thia-
mine (69%) and a proton pump inhibitor (PPi) (55%).
The majority of patients had whole blood thiamine 
diphosphate concentrations (59%) within the normal ref-
erence interval (275–675  ng/gHb) and 40% of patients 
had whole blood thiamine diphosphate concentrations 
above the reference interval (> 675  ng/gHb). One-third 
of patients (33%) (n = 14) who had whole blood thiamine 
diphosphate concentrations above the reference interval 
(> 675 ng/gHb) (n = 42) at the time of study recruitment 
had been admitted to hospital and treated with paren-
teral thiamine within 1 month prior to the study related 
admission. The majority of patients (73%) had been pre-
scribed long-term oral thiamine supplementation (50 mg 
or 100 mg TDS) in the community prior to entering the 
study. Only one of the patients (< 1%) entered into the 
study had a whole blood thiamine concentration below 
the reference interval (< 275 ng/gHb).
In contrast, the majority of patients had serum magne-
sium concentrations that could be considered to be low 
(< 0.75 mmol/L; 60%) and had not been prescribed mag-
nesium (93%). When patients from this cohort (n = 81) 
were followed up at their next admission, the majority 
of patients (74%) still had serum magnesium concen-
trations below the reference interval (< 0.75  mmol/L) 
(median = 0.67 mmol/L, IQR 0.59–0.76 mmol/L, median 
time interval between samples = 126 days) (see Tables 1, 
2; Fig. 4).
The majority of patients (66%) were found to have 
plasma lactate concentrations above 2.0 mmol/L. When 
patients who had experienced a seizure in the 12-hour 
period prior to study enrolment (n = 29) were excluded 
from the analysis, the majority (60%) of the remaining 
patients (n = 74) had plasma lactate concentrations above 
2.0  mmol/L. The median plasma lactate concentration 
for this sub-set of patients (i.e. non-seizure related alco-
hol withdrawal syndrome presentations) was 2.4 mmol/L 
(IQR 1.6–4.5  mmol/L). The median plasma lactate con-
centration for patients recruited to the study with alco-
hol withdrawal syndrome who had experienced a seizure 
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Table 1 The relationship between clinicopathological characteristics and 1-year mortality in patients with AWS (n = 115)
1 Continuous data were analysed with Mann–Whitney U test and categorical data were analysed with Chi squared test
a Alcohol intake–alive: n = 54; dead: n = 3
Alive (n = 102) Dead (n = 13) p-value1
Age (years) 48 (39–54) 48 (35–60) 0.915
Male/female 75/27 13/0 0.035
BMI (kg/m2) 22.6 (20.9–26.2) 21.9 (18.8–29.2) 0.473
Clinical
 Alcohol intake (U/week)a 205 (134–280) 280 (140–350) 0.390
 GMAWS (at presentation) 4 (3, 4) 4 (4–5) 0.077
 GMAWS max 4 (3–5) 5 (4–6) 0.090
 GMAWS max (< 4/≥ 4) 38/63 1/12 0.033
 BDZ total (mg) 130 (50–240) 230 (55–320) 0.148
 Smoker (yes/no) 75/24 9/4 0.611
 Recent weight loss (yes/no) 65/28 11/1 0.114
 Gait disturbance (yes/no) 83/18 12/1 0.358
Laboratory
 Bilirubin (umol/L) 16 (10–28) 31 (13–75) 0.019
 Alk phos (U/L) 106 (92–137) 130 (95–180) 0.154
 Albumin (g/L) 39 (36–42) 37 (27.5–40) 0.106
 CRP (mg/L) 4 (2–11) 17 (7–30) 0.004
 AST 58 (34–98) 78 (29–131) 0.634
 ALT 38 (25–61) 35 (18–53) 0.185
 AST:ALT 1.6 (1.0–2.2) 1.9 (1.5–3.4) 0.038
 Urea (mmol/L) 3.4 (2.6–4.8) 3.2 (2.5–5.4) 0.569
 Sodium (mmol/L) 137 (134–140) 138 (136–141) 0.280
 Potassium (mmol/L) 4.0 (3.7–4.4) 4.0 (3.5–4.5) 0.555
 Serum magnesium (mmol/L) 0.72 (0.62–0.80) 0.53 (0.48–0.72) 0.006
 Plasma  H+ (nmol/L) 37 (33–40) 33 (27–40) 0.175
 Plasma  HCO3
− (mmol/L) 27 (25–32) 28 (24–35) 0.745
 MCV (fl) 95.4 (90.6–99.7) 100.4 (93.1–106.7) 0.059
 Platelets  (109/L) 239 (143–295) 175 (78–240) 0.092
 Whole blood TDP (ng/gHb) 595 (509–825) 670 (391–791) 0.720
 LDH (U/L) 257 (208–325) 272 (220–369) 0.373
 Glucose (mmol/L) 5.8 (5.3–7.5) 6.9 (5.9–7.7) 0.183
 Lactate (mmol/L) 2.3 (1.5–4.2) 3.8 (2.6–7.2) 0.011
 Follow‑up ‘next admission’ serum magnesium (mmol/L) 0.68 (0.59–0.76) 0.61 (0.49–0.67) 0.020
Medications
 Thiamine (yes/no) 77/23 2/11 0.978
 Magnesium (yes/no) 8/88 13/0 0.282
 PPi (yes/no) 59/40 4/9 0.506
 Diuretic (yes/no) 5/91 4/9 0.002
Admission profile
 Admitted within previous month (yes/no) 23/75 3/10 0.975
 ED presentations within 12 months 2 (1–5) 3 (2–7) 0.315
 Total number of admissions 14 (6–32) 14 (4–57) 0.466
 Length of stay (days) 4 (3–7) 8 (5–10) 0.027
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Table 2 The relationship between  circulating magnesium concentrations and  clinicopathological characteristics 
in patients with alcohol withdrawal syndrome (n = 111)
1 Continuous data were analysed with Mann–Whitney U test and categorical data were analysed with Chi squared test
a Alcohol intake:  Mg2+ ≥ and < 0.75 mmol/L: n = 22; n = 32
Serum magnesium (mmol/L) p-value1
≥ 0.75 (n = 46) < 0.75 (n = 65)
Age (years) 46 (35–49) 48 (40–54) 0.139
Male/female 33/13 53/12 0.226
BMI (kg/m2) 22.5 (20.9–24.8) 22.7 (20.5–27.1) 0.571
Dead at 1‑year (yes/no) 2/44 11/54 0.043
Clinical
 Alcohol intake (U/week)a 210 (145–280) 168 (42–420) 0.259
 GMAWS (at presentation) 3 (2–4) 4 (3–5) 0.006
 GMAWS max 3 (2–4) 4 (4–6) 0.001
 BDZ total (mg) 100 (40–210) 180 (50‑ 290) 0.335
 Smoker (yes/no) 31/13 50/14 0.368
 Recent weight loss (yes/no) 29/14 46/14 0.302
 Gait disturbance (yes/no) 35/11 56/8 0.120
Laboratory
 Bilirubin (umol/L) 12 (8–20) 17 (13–41) < 0.001
 Alk phos (U/L) 101 (90–138) 114 (94–140) 0.430
 Albumin (g/L) 39 (36–43) 38 (36–41) 0.168
 CRP (mg/L) 4.5 (1–10.5) 5 (2–14.3) 0.303
 AST 44 (31 75) 66 (41–213) 0.015
 ALT 37 (24–61) 38 (25–60) 0.854
 AST:ALT 1.4 (1.0–1.8) 1.6 (1.3–2.8) 0.004
 Urea (mmol/L) 3.3 (2.6–5.2) 3.3 (2.5–4.9) 0.593
 Sodium (mmol/L) 138 (134–141) 138 (134–139) 0.422
 Potassium (mmol/L) 4.1 (3.7–4.5) 4.0 (3.6–4.3) 0.437
 Plasma  H+ (nmol/L) 39 (35–40) 36 (31–39) 0.013
 Plasma  HCO3
− (mmol/L) 29 (24–33) 27 (25–31) 0.812
 MCV (fl) 95.2 (90.9–99.6) 95.7 (91.2–100.4) 0.418
 Platelets  (109/L) 256 (165–312) 204 (117–282) 0.020
 Follow‑up ‘next admission’ serum magnesium (mmol/L) 0.73 (0.66–0.79) 0.61 (0.55–0.68) < 0.001
 Whole blood TDP (ng/gHb) 642 (500–855) 591 (501–775) 0.305
 LDH (U/L) 240 (209–308) 269 (213–358) 0.333
 Glucose (mmol/L) 5.8 (5.4–7.2) 6.2 (5.3–7.9) 0.477
 Lactate (mmol/L) 2.3 (1.3–3.4) 2.9 (1.9–5.9) 0.023
Medications
 Thiamine (yes/no) 34/12 51/13 0.478
 Magnesium (yes/no) 5/41 3/57 0.259
 PPi (yes/no) 26/20 39/24 0.573
 Diuretic (yes/no) 1/44 8/53 0.048
Admission profile
 Admitted within previous month (yes/no) 14/31 11/52 0.077
 ED presentations within 12 months 3 (1–7) 2 (0–36) 0.923
 Total number of admissions 15 (6–33) 14 (0–172) 0.646
 Length of stay (days) 4 (3–7) 5 (1–29) 0.171
Page 9 of 13Maguire et al. J Transl Med          (2019) 17:384 
within 12 h of presentation (n = 29) was 2.5 mmol/L (IQR 
1.7–14.6  mmol/L). Serum magnesium concentrations 
were significantly associated with plasma lactate concen-
trations  (rs = − 0.234, p < 0.05).
At 1 year, 13 patients had died giving a mortality 
rate of 11%. The relationship between 1-year mortality 
and clinicopathological characteristics are shown in 
Table  1. On univariate analysis, male gender (p < 0.05), 
BMI < 20  kg/m2 (p < 0.01), GMAWS max ≥ 4 (p < 0.05), 
elevated plasma lactate (p < 0.01), low serum albumin 
(p < 0.05), elevated serum CRP (p < 0.05), low serum mag-
nesium at time of recruitment to study (p < 0.05) and 
Fig. 4 Diagrammatic representation of relative change between initial serum magnesium concentrations and ‘next admission’ serum magnesium 
concentrations in prospective observational study of patients presenting to the Emergency Department with alcohol withdrawal syndrome (n = 81)
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low serum magnesium concentration at next admission 
(p < 0.05) were associated with death at 1-year.
The relationship between low serum magnesium con-
centrations and clinicopathological characteristics is 
shown in Table 2. Low serum magnesium concentrations 
were associated with a higher GMAWS score at presenta-
tion (p < 0.01), higher GMAWS max (p = 0.001), elevated 
hydrogen ion concentrations (> 45 nmol/L) (p < 0.05) and 
death at 1-year (p < 0.05).
Binary logistic regression analysis confirmed that 
patients who had low serum magnesium concentrations 
(< 0.75 mmol/L) were 3 times more likely to have a severe 
episode of AWS (GMAWS ≥ 4) when compared to those 
patients who had serum magnesium concentrations 
within the normal reference interval (O.R. = 3.0, 95% CI 
(1.1–8.0), p < 0.05).
Discussion
The results of the present prospective study show that the 
majority of patients with AWS had thiamine concentra-
tions within or above the normal interval. In contrast, the 
majority of patients had low serum magnesium concen-
trations at presentation. Furthermore, low serum mag-
nesium concentrations (< 0.75  mmol/L) were associated 
with increased risk of mortality at 1-year among patients 
admitted to hospital with AWS. These results highlight 
the importance of a low serum magnesium concentra-
tion, and its lack of treatment, in outcome of patients 
presenting with AWS.
It was of interest that only 1 patient (< 1%) in the cohort 
(n = 115) had a baseline circulating thiamine diphosphate 
measurement below the reference interval (< 275  ng/
gHb). Indeed, almost 40% of patients had circulating 
thiamine diphosphate concentrations above the upper 
limit of the reference interval (> 675  ng/gHb), and had 
been prescribed thiamine (73%). In contrast, approxi-
mately 60% of patients had low serum magnesium con-
centrations (< 0.75 mmol/L) and had not been prescribed 
magnesium (93%). Furthermore, serum magnesium con-
centrations remained low (< 0.75  mmol/L) when meas-
ured during the next acute admission (Fig.  4). These 
results are consistent with a recent retrospective study 
(n = 380) that reported a prevalence of low serum mag-
nesium concentrations (< 0.75 mmol/L) (> 60%) and 17% 
1-year mortality for patients presenting with AWS [9].
The majority of patients (60%) who had circulating thi-
amine diphosphate concentrations above the reference 
interval (> 675 ng/gHb) at the time of study recruitment 
had been admitted to hospital and treated with paren-
teral thiamine within 1 month prior to the study related 
admission. However, in routine clinical practice thiamine 
concentrations are rarely measured, and if so, results are 
only available weeks later. Hence, the established clinical 
appreciation of the importance of thiamine deficiency 
in exacerbating symptoms in patients with AWS would 
appear to have resulted in the empirical administra-
tion of commercially available thiamine  (Pabrinex®) to 
patients with AWS admitted to the general hospital set-
ting [12]. In the present cohort of patients, community 
treatment with oral thiamine combined with the intrave-
nous administration of thiamine during frequent hospital 
admissions may account for the normal and high circu-
lating concentrations of whole blood thiamine diphos-
phate observed. In contrast, in the case of magnesium, 
although results are obtained within minutes/hours of 
sampling, low serum magnesium concentrations were 
not routinely supplemented. The infrequency of mag-
nesium supplementation in the context of low serum 
magnesium concentrations may reflect a lack of clinician 
awareness that exists regarding the clinical significance 
and prevalence of magnesium deficiency among AUD 
patients. This in turn likely reflects a paucity of evidence 
regarding the prevalence of magnesium deficiency and 
other micronutrient deficiencies (e.g. vitamin C) among 
the AUD patient population [36]. Although it has been 
understood biochemically for decades that thiamine is 
dependent upon magnesium for optimal metabolism, in 
the absence of clinical data this has not translated into 
widespread clinical practice to date.
The measurement and interpretation of thiamine levels 
is quite problematic and the ideal method remains con-
tentious [37]. Indeed, Cook et al. observed in their review 
that it was the activity of thiamine, which was relevant, 
rather than the finite mass available [38]. Erythrocyte 
transketolase activity (ETKA) is a functional marker of 
thiamine dependent enzyme activity which was com-
monly used to measure thiamine status until the late 
1990s, however this method of routine measurement 
of thiamine status fell out of favor due to difficulty with 
standardization, inter-laboratory variation and the advent 
of high performance liquid chromatography (HPLC), 
which enabled direct measurement of TDP mass [39, 40]. 
Direct measurement of erythrocyte and/or whole blood 
thiamine concentrations is now more widely available 
[35] and has the advantage of remaining consistent in the 
context of the systemic inflammatory response [41, 42]. 
Nonetheless, it is of note that significant enhancement of 
basal erythrocyte transketolase activity (ETKA) has been 
demonstrated in response to co-administration of thia-
mine and magnesium, as compared to thiamine alone, in 
a cohort of alcohol dependent patients [16].
On the basis of the present results, it may be proposed 
that further studies to elucidate the pharmacokinetics 
of parenteral thiamine supplementation are required to 
clarify the safe therapeutic window during which patients 
with AWS may not require further treatment with 
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parenteral thiamine. The basis of Wernicke’s encephalop-
athy (WE) is not clear [18]. However, it is clear that WE is 
exacerbated by thiamine deficiency [33, 43]. Under nor-
mal physiological and nutritional conditions, the aver-
age adult human has approximately a 3-week reserve of 
thiamine in the liver and skeletal muscle. These reserves 
become rapidly depleted in alcohol related disease [43, 
44]. Therefore, given the present results, it is likely that 
these patients were compliant with thiamine supplemen-
tation as routinely prescribed and confirm the success of 
a therapeutic strategy for a patient group who are known 
to be at high risk of thiamine deficiency. Overall, the clin-
ical consequences of under-treating thiamine deficiency 
are potentially devastating, while treatment with paren-
teral thiamine appears to have a good safety profile and 
is relatively inexpensive. However, it is not clear whether 
chronically high circulating thiamine may have a detri-
mental effect on health.
The basis of the finding that low serum magnesium 
concentrations (< 0.75 mmol/L) were independently asso-
ciated with more severe alcohol withdrawal syndrome 
(GMAWS ≥ 4) is not clear. However, the present results 
are in keeping with in vitro data that confirms the role of 
magnesium in stabilisation of the NMDA receptor [45]. 
NMDA receptors require binding of glutamate and gly-
cine, combined with the relief of the voltage-dependent 
magnesium block, to open the calcium ion conductive 
pore [45]. The association between higher maximal AWS 
scores (GMAWS max) and low serum magnesium con-
centrations may reflect the reliance of the NMDA recep-
tor on the stabilizing effect of magnesium (see Table  2) 
[46, 47]. Hence, a biochemical cause for AWS related sei-
zure activity may be converted to a structural focus for 
seizure activity and result in lower subsequent seizure 
thresholds [46]. This process of alcohol withdrawal ‘sei-
zure kindling’ may be reflected in the strong association 
between a documented history of previous alcohol with-
drawal seizures that was noted in a high proportion of 
patients (97%) who had sustained an alcohol withdrawal 
seizure in the 12-h period prior to recruitment to the 
study.
The present study also reports data relating to the 
interrelationship between thiamine and magnesium sta-
tus in intermediary metabolism, as reflected in plasma 
lactate concentrations. Serum magnesium concentra-
tions were significantly associated with plasma lactate 
concentrations. One possible explanation of the associa-
tion between low serum magnesium concentrations and 
raised plasma lactate concentrations, may be that mag-
nesium deficiency mediated compromise of PDH activity 
can result in pyruvate being unable to gain access into the 
mitochondrion for conversion to acetyl-CoA and thereby 
onto Krebs cycle (Figs.  1, 2) [28]. The resulting ‘glut’ of 
pyruvate in the cytosol may trigger up-regulation of LDH 
activity [48]. LDH mediates the increased production of 
lactate, which accumulates in the cytosol [49]. This may 
be considered the suboptimal metabolism of glucose 
i.e. a pseudo-hypoxic ‘dirty burn’ (Fig.  2) [7]. Given the 
requirement of PDH for TDP and magnesium, chronic 
ingestion of excessive amounts of alcohol in the con-
text of a micronutrient poor diet may therefore result in 
pseudo-hypoxic dysregulation of glucose metabolism (i.e. 
‘dirty burn’ metabolism) with increased lactate produc-
tion (Fig. 2) [7, 50].
Interestingly, elevated plasma lactate was significantly 
associated with 1-year mortality and this may reflect a 
chronic loss of oxidative resilience among this patient 
group. Alcohol related cirrhotic liver disease is reported 
to cause increased splanchnic and systemic plasma lac-
tate concentrations [51], however associations between 
plasma lactate and serum bilirubin concentrations or 
plasma lactate concentrations and AST:ALT ratio > 2 
were not significant. Overall, this series of patients would 
appear to represent the largest cohort of AWS patients to 
have non-seizure related elevated plasma lactate concen-
trations recorded to date.
Limitations
The present study sample may not be representative of 
all patients experiencing alcohol use disorder. Patients 
who experience AWS represent a group of AUD patients 
who have a very high level of dependence and of with-
drawal complications. Indeed, the patients described in 
the present study represent a group of AUD patients who 
have been treated with previous thiamine supplemen-
tation. Furthermore, it is worth considering that in the 
context of such high dose supplementation, other B-vita-
mins apart from thiamine (e.g. nicotinamide, pyridoxine 
and riboflavin) may also be within their normal interval 
ranges for those patients who receive frequent high dose 
parenteral therapy. Another important limitation of this 
study is the lack of measurement of other micronutrients 
e.g. B-vitamins, vitamin C and trace elements e.g. sele-
nium and zinc. Further studies that present data relat-
ing to more comprehensive nutritional assessment are 
required in order to better nutritionally phenotype these 
individuals.
Also, the relatively small sample size (n = 115) may be 
considered a limitation of this study. Nonetheless, this 
sample presenting prospective data relating to the clin-
icopathological characteristics of patients experiencing 
AWS is one of the largest reported to date.
The underlying mechanisms that could explain a rela-
tion between low circulating magnesium concentrations 
and increased all-cause mortality remain to be estab-
lished. For example, it may be postulated that those 
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patients with low circulating magnesium concentrations 
may have had poorer access to care, therefore they were 
less likely to be offered supplementation and may have 
died sooner, but without any direct link between these 
two conditions. To establish the potential benefit of mag-
nesium supplementation, it will be necessary to carry out 
a randomised controlled trial of magnesium supplemen-
tation in patients with AWS.
Conclusion
The prevalence of low circulating thiamine concentra-
tions were rare and it was regularly prescribed in patients 
with AWS. In contrast, low serum magnesium concentra-
tions were common and not prescribed. Low serum mag-
nesium was associated more severe AWS and increased 
1-year mortality.
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